Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

How to Train your T cells: Overcoming Immune Dysfunction in Multiple Myeloma.

Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV.

Clin Cancer Res. 2019 Oct 31. pii: clincanres.2111.2019. doi: 10.1158/1078-0432.CCR-19-2111. [Epub ahead of print]

PMID:
31672768
2.

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV.

J Clin Oncol. 2019 Oct 25:JCO1901740. doi: 10.1200/JCO.19.01740. [Epub ahead of print]

PMID:
31652094
3.

Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?

Dhodapkar MV, Dhodapkar KM.

Front Immunol. 2019 Oct 10;10:2385. doi: 10.3389/fimmu.2019.02385. eCollection 2019. Review.

4.

SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.

Madduri D, Dhodapkar MV, Lonial S, Jagannath S, Cho HJ.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):537-544. doi: 10.1016/j.clml.2019.08.002. Epub 2019 Aug 7. Review.

PMID:
31427259
5.

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Barwick BG, Neri P, Bahlis NJ, Nooka AK, Dhodapkar MV, Jaye DL, Hofmeister CC, Kaufman JL, Gupta VA, Auclair D, Keats JJ, Lonial S, Vertino PM, Boise LH.

Nat Commun. 2019 Apr 23;10(1):1911. doi: 10.1038/s41467-019-09555-6.

6.

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, Hofmeister CC, Boise LH, Lonial S, Kemp ML, Dhodapkar KM, Dhodapkar MV.

JCI Insight. 2019 Apr 23;5. pii: 127807. doi: 10.1172/jci.insight.127807.

7.

Daratumumab in multiple myeloma.

Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, Sullivan HC, Neish AS, Dhodapkar MV, Lonial S.

Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5. Review.

PMID:
30951198
8.

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.

Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T.

J Clin Oncol. 2019 May 10;37(14):1228-1263. doi: 10.1200/JCO.18.02096. Epub 2019 Apr 1.

PMID:
30932732
9.

Navigating the Fas lane to improved cellular therapy for cancer.

Dhodapkar MV.

J Clin Invest. 2019 Feb 25;129(4):1522-1523. doi: 10.1172/JCI127581. eCollection 2019 Feb 25.

10.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2019 Feb 21;4(4). pii: 127684. doi: 10.1172/jci.insight.127684. eCollection 2019 Feb 21. No abstract available.

11.

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR.

J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5. Review.

12.

Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.

Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, Boise LH, Dhodapkar MV, Gleason C, Nooka AK, Lonial S.

Cancer. 2019 Feb 1;125(3):416-423. doi: 10.1002/cncr.31718. Epub 2018 Oct 17.

PMID:
30332496
13.

Checkpoint Inhibition in Myeloma: Opportunities and Challenges.

Costa F, Das R, Kini Bailur J, Dhodapkar K, Dhodapkar MV.

Front Immunol. 2018 Sep 26;9:2204. doi: 10.3389/fimmu.2018.02204. eCollection 2018. Review.

14.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2018 Apr 19;3(8). pii: 120505. doi: 10.1172/jci.insight.120505. eCollection 2018 Apr 19. Erratum in: JCI Insight. 2019 Feb 21;4(4):.

15.

Antigen-mediated regulation in monoclonal gammopathies and myeloma.

Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV.

JCI Insight. 2018 Apr 19;3(8). pii: 98259. doi: 10.1172/jci.insight.98259. eCollection 2018 Apr 19.

16.

MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association.

Weinreb NJ, Mistry PK, Rosenbloom BE, Dhodapkar MV.

Blood. 2018 May 31;131(22):2500-2501. doi: 10.1182/blood-2018-02-834689. Epub 2018 Apr 12. No abstract available.

17.

Early B cell changes predict autoimmunity following combination immune checkpoint blockade.

Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM.

J Clin Invest. 2018 Feb 1;128(2):715-720. doi: 10.1172/JCI96798. Epub 2018 Jan 8.

18.

Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy.

Kini Bailur J, Mehta S, Zhang L, Neparidze N, Parker T, Bar N, Anderson T, Xu ML, Dhodapkar KM, Dhodapkar MV.

Blood Adv. 2017 Nov 20;1(25):2343-2347. doi: 10.1182/bloodadvances.2017012732. eCollection 2017 Nov 28. Erratum in: Blood Adv. 2018 Jan 09;2(1):75. Blood Adv. 2018 Jan 9;2(1):75.

19.

Natural Killer T Cells in Cancer Immunotherapy.

Nair S, Dhodapkar MV.

Front Immunol. 2017 Sep 22;8:1178. doi: 10.3389/fimmu.2017.01178. eCollection 2017. Review.

20.

Hematologic Malignancies: Plasma Cell Disorders.

Dhodapkar MV, Borrello I, Cohen AD, Stadtmauer EA.

Am Soc Clin Oncol Educ Book. 2017;37:561-568. doi: 10.14694/EDBK_175546. Review.

PMID:
28561703
21.

Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.

Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV.

Clin Lymphoma Myeloma Leuk. 2017 May;17(5):296-304.e2. doi: 10.1016/j.clml.2017.02.025. Epub 2017 Mar 7.

22.

Systematic evaluation of immune regulation and modulation.

Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B.

J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. Review.

23.

Type II NKT Cells and Their Emerging Role in Health and Disease.

Dhodapkar MV, Kumar V.

J Immunol. 2017 Feb 1;198(3):1015-1021. doi: 10.4049/jimmunol.1601399. Review.

24.

Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.

Boddupalli CS, Bar N, Kadaveru K, Krauthammer M, Pornputtapong N, Mai Z, Ariyan S, Narayan D, Kluger H, Deng Y, Verma R, Das R, Bacchiocchi A, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM.

JCI Insight. 2016 Dec 22;1(21):e88955. doi: 10.1172/jci.insight.88955.

25.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

26.

Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice.

Das R, Strowig T, Verma R, Koduru S, Hafemann A, Hopf S, Kocoglu MH, Borsotti C, Zhang L, Branagan A, Eynon E, Manz MG, Flavell RA, Dhodapkar MV.

Nat Med. 2016 Nov;22(11):1351-1357. doi: 10.1038/nm.4202. Epub 2016 Oct 10.

27.

MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Dhodapkar MV.

Blood. 2016 Dec 8;128(23):2599-2606. Epub 2016 Oct 13. Review.

28.

ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells.

Boddupalli CS, Nair S, Gray SM, Nowyhed HN, Verma R, Gibson JA, Abraham C, Narayan D, Vasquez J, Hedrick CC, Flavell RA, Dhodapkar KM, Kaech SM, Dhodapkar MV.

J Clin Invest. 2016 Oct 3;126(10):3905-3916. doi: 10.1172/JCI85329. Epub 2016 Sep 12.

29.

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma.

Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV.

N Engl J Med. 2016 Feb 11;374(6):555-61. doi: 10.1056/NEJMoa1508808.

30.

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.

Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, Soni S, Crowley JJ, Orlowski RZ, Barlogie B.

Blood. 2015 Nov 26;126(22):2475-8. doi: 10.1182/blood-2015-03-632919. Epub 2015 Oct 14.

31.

Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart.

Bar N, Parker TL, Dhodapkar MV.

J Clin Oncol. 2015 Nov 10;33(32):3689-90. doi: 10.1200/JCO.2015.63.2224. Epub 2015 Sep 14. No abstract available.

PMID:
26371139
32.

Immune Modulation in Hematologic Malignancies.

Dhodapkar MV, Dhodapkar KM.

Semin Oncol. 2015 Aug;42(4):617-25. doi: 10.1053/j.seminoncol.2015.05.009. Epub 2015 Jun 3. Review.

33.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

34.

Trial watch: Dendritic cell-based anticancer therapy.

Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 21;3(11):e963424. eCollection 2014 Nov. Review.

35.

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.

Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV.

Blood. 2015 Jun 25;125(26):4042-51. doi: 10.1182/blood-2014-11-611426. Epub 2015 Apr 13.

36.

Recent advances and new opportunities for targeting human dendritic cells in situ.

Dhodapkar MV, Dhodapkar KM.

Oncoimmunology. 2014 Aug 3;3(8):e954832. eCollection 2014.

37.

Conditional overexpression of TGFβ1 promotes pulmonary inflammation, apoptosis and mortality via TGFβR2 in the developing mouse lung.

Sureshbabu A, Syed MA, Boddupalli CS, Dhodapkar MV, Homer RJ, Minoo P, Bhandari V.

Respir Res. 2015 Jan 16;16:4. doi: 10.1186/s12931-014-0162-6.

38.

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.

Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM.

J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24.

39.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

40.

Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation.

Nair S, Boddupalli CS, Verma R, Liu J, Yang R, Pastores GM, Mistry PK, Dhodapkar MV.

Blood. 2015 Feb 19;125(8):1256-71. doi: 10.1182/blood-2014-09-600270. Epub 2014 Dec 11.

41.

Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk.

Sehgal K, Ragheb R, Fahmy TM, Dhodapkar MV, Dhodapkar KM.

J Immunol. 2014 Sep 1;193(5):2297-305. doi: 10.4049/jimmunol.1400489. Epub 2014 Jul 30.

42.

Targeting human dendritic cells in situ to improve vaccines.

Sehgal K, Dhodapkar KM, Dhodapkar MV.

Immunol Lett. 2014 Nov;162(1 Pt A):59-67. doi: 10.1016/j.imlet.2014.07.004. Epub 2014 Jul 27. Review.

43.

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.

Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker A, Vitale L, Yellin M, Davis T, Keler T.

Sci Transl Med. 2014 Apr 16;6(232):232ra51. doi: 10.1126/scitranslmed.3008068.

44.

Serial exome analysis of disease progression in premalignant gammopathies.

Zhao S, Choi M, Heuck C, Mane S, Barlogie B, Lifton RP, Dhodapkar MV.

Leukemia. 2014 Jul;28(7):1548-52. doi: 10.1038/leu.2014.59. Epub 2014 Feb 5. No abstract available.

45.

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Orlowski RZ, Barlogie B.

Blood. 2014 Jan 2;123(1):78-85. doi: 10.1182/blood-2013-07-515239. Epub 2013 Oct 21.

46.

SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer.

Dhodapkar KM, Gettinger SN, Das R, Zebroski H, Dhodapkar MV.

Oncoimmunology. 2013 Jul 1;2(7):e25205. Epub 2013 Jun 10.

47.

Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?

Dhodapkar MV.

Cancer Prev Res (Phila). 2013 Mar;6(3):173-6. doi: 10.1158/1940-6207.CAPR-13-0011. Epub 2013 Jan 22. Review.

48.

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.

Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, Miesowicz F, Dhodapkar KM, Dhodapkar MV.

Blood. 2013 Jan 17;121(3):423-30. doi: 10.1182/blood-2012-06-435503. Epub 2012 Oct 24.

49.

Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma.

Koduru S, Wong E, Strowig T, Sundaram R, Zhang L, Strout MP, Flavell RA, Schatz DG, Dhodapkar KM, Dhodapkar MV.

Blood. 2012 Mar 8;119(10):2302-9. doi: 10.1182/blood-2011-08-376236. Epub 2012 Jan 10.

50.

Adipokines in MM: time to trim the fat.

Dhodapkar MV.

Blood. 2011 Nov 24;118(22):5716-7. doi: 10.1182/blood-2011-10-379834. No abstract available.

PMID:
22123904

Supplemental Content

Loading ...
Support Center